Literature DB >> 33077524

Erythrocytosis induced by sodium-glucose cotransporter-2 inhibitors.

Benjamin Chin-Yee1, Ziad Solh2, Cyrus Hsia3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33077524      PMCID： PMC7588208          DOI： 10.1503/cmaj.76686

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  7 in total

1.  Risk of Erythrocytosis During Concomitant Testosterone and SGLT2-Inhibitor Treatment: A Warning From Two Clinical Cases.

Authors:  Giovanna Motta; Marco Zavattaro; Francesco Romeo; Fabio Lanfranco; Fabio Broglio
Journal:  J Clin Endocrinol Metab       Date:  2019-03-01       Impact factor: 5.958

2.  Unmasking and aggravation of polycythemia vera by canagliflozin.

Authors:  L Das; A Bhansali; R Walia
Journal:  Diabet Med       Date:  2018-11       Impact factor: 4.359

3.  Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease.

Authors:  C David Mazer; Gregory M T Hare; Philip W Connelly; Richard E Gilbert; Nadine Shehata; Adrian Quan; Hwee Teoh; Lawrence A Leiter; Bernard Zinman; Peter Jüni; Fei Zuo; Nikhil Mistry; Kevin E Thorpe; Ronald M Goldenberg; Andrew T Yan; Kim A Connelly; Subodh Verma
Journal:  Circulation       Date:  2019-11-11       Impact factor: 29.690

4.  How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.

Authors:  Silvio E Inzucchi; Bernard Zinman; David Fitchett; Christoph Wanner; Ele Ferrannini; Martin Schumacher; Claudia Schmoor; Kristin Ohneberg; Odd Erik Johansen; Jyothis T George; Stefan Hantel; Erich Bluhmki; John M Lachin
Journal:  Diabetes Care       Date:  2017-12-04       Impact factor: 19.112

Review 5.  Investigation and management of erythrocytosis.

Authors:  Siraj Mithoowani; Marissa Laureano; Mark A Crowther; Christopher M Hillis
Journal:  CMAJ       Date:  2020-08-10       Impact factor: 8.262

6.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

7.  Marked erythrocytosis during treatment with sodium glucose cotransporter-2 inhibitors-report of two cases.

Authors:  Ritesh Gupta; Aanchal Gupta; Mitu Shrikhande; Kanika Tyagi; Amerta Ghosh; Anoop Misra
Journal:  Diabetes Res Clin Pract       Date:  2020-03-26       Impact factor: 5.602
  7 in total
  1 in total

1.  Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study.

Authors:  Carlos King Ho Wong; Kristy Tsz Kwan Lau; Eric Ho Man Tang; Chi Ho Lee; Carmen Yu Yan Lee; Yu Cho Woo; Ivan Chi Ho Au; Kathryn Choon Beng Tan; David Tak Wai Lui
Journal:  Cardiovasc Diabetol       Date:  2022-06-03       Impact factor: 8.949
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.